Medicines, 2013
Shortlist up to four to read them side by side.
1,376 medicine recalls FDA’s Enforcement Report published in 2013, newest first; 18,075 in all since 2012.
FDA’s medicine recalls, as its Enforcement Report classifies them, from June 2012. Lists of FDA’s records can’t be saved for alerts: openFDA asks that its data not be used to alert the public (openFDA); FDA’s own emails do that. Copied Nov 6, 2026.
1,376of 1,376 medicine recallsshown with your filters
The list
- Medicine recall Methylcobalamin Inj 1mg/ml MDV, 10 ml, 15 ml, 20 ml, 30 ml, 4x30 ml Subcutaneous, 90 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Methylcobalamin Inj 5mg/ml MDV: 5 ml, 10 ml, 12 ml, 20 ml Subcutaneous, 90 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Methylcobalamin 5mg/ml Inj Syr, 10x0.4syr Subcutaneous, 90 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Methylcobalamin Inj 2.5mg/ml MDV, 10 ml Subcutaneous, 90 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Methylcobalamin Inj 25mg/ml Syr: 8x0.06mlsyr, 10x0.06 ml syr, 12x0.06 ml syr Subcutaneous, 30 and 90 day… Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Hydroxyprogesterone Inj 250mg/ml MDV, 5 ml Intramuscular, 30 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Renacidin Irrigation: 1000 ml,1120ml Bladder Irrigation, 30 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Gentamicin 24mg/60ml Irrigation, 15x60ml Syr Irrigation, 14 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Glutathione 200mg/ml Inj SDV: 3x50ml 14 day expiration, 1x50ml 21 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall M.I.C.+B12 Inj MDV: 3x50ml, 4x50 ml 90 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Lidocaine 2% Inj MDV, 20 ml 30 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Meperidine 100mg/ml MDV, 5ml 90 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Pyridoxine 100mg/ml Inj MDV, 1X30 ml 30 day expiration Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Seasonale(R) (Levonorgestrel/Ethinyl Estradiol Tablets), 0.15 mg/0.03 mg, 3 extended-cycle tablet dispensers,… Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing Class IIIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall Camrese(TM) (Levonorgestrel/Ethinyl Estradiol Tablets), 0.15 mg/0.03 mg and Ethinyl Estradiol 0.01 Tablets, 2… Failed Impurity/Degradation Specifications; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) detected during impurity testing Class IIIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall Lisinopril Tablets, USP, 30 mg Labeling: Label Error on Declared Strength: Incorrect strength on side display panel of label Class IIIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall Camila 0.35 mg Tablets, 6 cards of 28 pills, Dist Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing Class IIIFDA’s classJun 5, 2013in FDA’s Enforcement ReportMissourithe one state its words name PublishedJun 5, 2013ClassClass IIIStatusTerminatedWhereMissouri
- Medicine recall Ropinirole hydrochloride tablets, USP 4 mg, 100-count bottle (NDC 0378-5504-01) Labeling: Label Error on Declared Strength- Unopened bottles of Ropinirole USP 3 mg tablets was found to be incorrectly labeled as Ropinirole USP 4 mg tablets.. Class IIFDA’s classJun 5, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedJun 5, 2013ClassClass IIStatusTerminatedWhereNationwide
- Medicine recall Rite Aid brand Maximum Strength Tussin Cough & Cold Mucus Relief CF, (dextromethorphan HBr 10 mg, guaifenesin… Presence of Precipitate; white substance confirmed as Guaifenesin, an active ingredient was observed in some bottles. Class IIIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 9 states named PublishedMay 29, 2013ClassClass IIIStatusTerminatedWhereNationwide, and Alabama, Connecticut, Maryland, Michigan, North Carolina, New York, Oregon, Pennsylvania and West Virginia named
- Medicine recall Lamisil AT (terbinafine hydrochloride cream 1% antifungal), 24 g (.85 oz) tube, Novartis Consumer Health,… Labeling: Incorrect or Missing Lot and/or Expiration date; The Lot and/or Expiration date on the tube may not be legible in this lot. Class IIIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word for where it went PublishedMay 29, 2013ClassClass IIIStatusTerminatedWhereNationwide
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 25 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 50 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 75 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 88 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 100 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 112 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 125 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 137 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 175 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg Subpotent Drug: The products were below specification for potency at the expiry stability point. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 1 state named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Puerto Rico named
- Medicine recall Levothroid (levothyroxine sodium tablets, USP) , 50 mcg cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.050 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Levothroid (levothyroxine sodium tablets, USP) , 75 mcg cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.075 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Levothroid (levothyroxine sodium tablets, USP), 88 mcg cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.088 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.100 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.112 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.125 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.137 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.150 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.175 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Lloyd Thyro-Tab 0.200 mg. cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Levothroid (levothyroxine sodium tablets, USP), 100 mcg cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Levothroid (levothyroxine sodium tablets, USP), 112 mcg cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Levothroid (levothyroxine sodium tablets, USP) , 125 mcg cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
- Medicine recall Levothroid (levothyroxine sodium tablets, USP), 137 mcg cGMP deviations; After quality review of stability failures in previous lots, there is insufficient data to determine that other lots are not affected. Class IIFDA’s classMay 29, 2013in FDA’s Enforcement ReportNationwideFDA’s word, and 2 states named PublishedMay 29, 2013ClassClass IIStatusTerminatedWhereNationwide, and Missouri and Puerto Rico named
Nothing matches all of these.
Remove a filter to see more. Each one is a fact FDA’s record publishes, so a recall can be left out because its record is silent on it.
Source:
FDA, Drug recall enforcement reports. Released Nov 3, 2026. Updated weekly.
Recalls of food, medicines, medical devices, pet food and animal drugs are from the U.S. Food and Drug Administration (FDA). FDA does not endorse Hearth Record. openFDA: “Do not rely on openFDA to make decisions regarding medical care.”
Your shortlist0 of 4
Add one more to compare.